Literature DB >> 26778772

The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy.

Roy O Mathew1, Ali Nayer2, Arif Asif3.   

Abstract

The endothelium plays a pivotal role in vascular biology. The endothelium is the primary site of injury in thrombotic microangiopathies including malignant hypertension. Endothelial injury in thrombotic microangiopathies is the result of increased shear stress, toxins, and/or dysregulated complement activation. Endothelial injury can lead to microvascular thrombosis resulting in ischemia and organ dysfunction, the clinical hallmarks of thrombotic microangiopathies. Currently, available therapies target the underlying mechanisms that lead to endothelial injury in these conditions. Ongoing investigations aim at identifying drugs that protect the endothelium. Published by Elsevier Inc.

Entities:  

Keywords:  Malignant hypertension; endothelial dysfunction; hemolytic uremic syndrome; thrombotic microangiopathy

Mesh:

Substances:

Year:  2015        PMID: 26778772     DOI: 10.1016/j.jash.2015.12.007

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  19 in total

1.  Complement Activation and Thrombotic Microangiopathies.

Authors:  Marta Palomo; Miquel Blasco; Patricia Molina; Miquel Lozano; Manuel Praga; Sergi Torramade-Moix; Julia Martinez-Sanchez; Joan Cid; Gines Escolar; Enric Carreras; Cristina Paules; Fatima Crispi; Luis F Quintana; Esteban Poch; Lida Rodas; Emma Goma; Johann Morelle; Mario Espinosa; Enrique Morales; Ana Avila; Virginia Cabello; Gema Ariceta; Sara Chocron; Joaquin Manrique; Xoana Barros; Nadia Martin; Ana Huerta; Gloria M Fraga-Rodriguez; Mercedes Cao; Marisa Martin; Ana Maria Romera; Francesc Moreso; Anna Manonelles; Eduard Gratacos; Arturo Pereira; Josep M Campistol; Maribel Diaz-Ricart
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

Review 2.  Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review.

Authors:  Jon Badiola; Nuria Navarrete-Navarrete; José Mario Sabio
Journal:  Rheumatol Int       Date:  2018-12-15       Impact factor: 2.631

Review 3.  Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy.

Authors:  Marie Scully
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

Review 5.  HUS and atypical HUS.

Authors:  T Sakari Jokiranta
Journal:  Blood       Date:  2017-04-17       Impact factor: 25.476

Review 6.  Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome.

Authors:  Yu-Min Shen
Journal:  Thromb J       Date:  2016-10-04

7.  The potential role of complements in cocaine-induced thrombotic microangiopathy.

Authors:  Adriana Dejman; Seyed Navid Alavi; David B Thomas; Alexandra Stefanovic; Arif Asif; Ali Nayer
Journal:  Clin Kidney J       Date:  2017-07-06

8.  Eculizumab in secondary atypical haemolytic uraemic syndrome.

Authors:  Teresa Cavero; Cristina Rabasco; Antía López; Elena Román; Ana Ávila; Ángel Sevillano; Ana Huerta; Jorge Rojas-Rivera; Carolina Fuentes; Miquel Blasco; Ana Jarque; Alba García; Santiago Mendizabal; Eva Gavela; Manuel Macía; Luis F Quintana; Ana María Romera; Josefa Borrego; Emi Arjona; Mario Espinosa; José Portolés; Carolina Gracia-Iguacel; Emilio González-Parra; Pedro Aljama; Enrique Morales; Mercedes Cao; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

Review 9.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

10.  TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature.

Authors:  Céline Louis; Sandrine Vijgen; Kaveh Samii; Yves Chalandon; Louis Terriou; David Launay; David C Fajgenbaum; Jörg D Seebach; Yannick D Muller
Journal:  Front Med (Lausanne)       Date:  2017-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.